IMNN · Imunon, Inc.

Imunon reported a net loss of $4.3 million for Q1 2026, slightly wider than the $4.1 million loss in Q1 2025, primarily due to increased research and development expenses tied to the ongoing Phase 3 OVATION 3 trial. R&D costs rose to $2.3 million from $2.2 million, while G&A remained flat at $2.0 million. The company ended the quarter with $4.8 million in cash, down from $8.8 million at year-end 2025, reflecting cash used in operations of $4.0 million. The most significant business update was the final Phase 2 OVATION 2 data, which showed a median overall survival improvement of 14.7 months (45.1 vs 30.4 months) for IMNN-001 plus standard of care versus standard of care alone. In patients who also received PARP inhibitors as maintenance therapy, the OS benefit increased to 24.2 months (65.6 vs 41.4 months). Management highlighted that enrollment in the pivotal Phase 3 OVATION 3 trial is ahead of plan, with completion expected by Q1 2029, and that the FDA has aligned on the Phase 3 protocol, confirming a path to BLA filing. The company also completed a strategic reorganization in February 2026 to reduce operating expenses and focus on the Phase 3 study. The press release contained forward-looking statements regarding the potential of IMNN-001 and the timing of clinical milestones.